Abstract
Purpose: To determine the safety and efficacy of corneal photovitrification (CPV), a new corneal laser procedure, for vision improvement in patients with late stage dry age-related macular degeneration (AMD). Design: Retrospective observational cohort study Participants: 32 eyes of 17 patients with late stage dry AMD; each eye received a single CPV corneal laser procedure and had 12 months (12m) post-treatment (Tx) follow-up. Methods: Pre- and post-Tx examinations included slit-lamp biomicroscopy, subjective manifest refraction, best corrected distance and near visual acuity (BCDVA and BCNVA), and potential visual acuity (PVA). Additional examinations including contrast sensitivity (CS), corneal topography (CT), ray tracing aberrometry (RTA) and microperimetry (MP) were obtained for a subgroup (n=12) of eyes. Main Outcome Measures: BCDVA, BCNVA, PVA, CS, CT, RTA and MP measurements Results: Safety – There were no complications or adverse events. Efficacy – Mean (± SD) BCDVA improved significantly (p < 0.004) from 20/238 (1.08 logMAR) at baseline to 20/144 (0.86 logMAR) at 12m post-Tx corresponding to 11.0 (± 13.1) letters gained. Mean contrast sensitivity improved significantly (p < 0.05) by a factor of 1.86 from baseline at 12m post-Tx. Conclusions: Subject to the limitation of a small sample size, this pilot study indicates that the CPV corneal laser procedure is safe and efficacious for vision improvement in patients with late stage dry AMD. The CPV Tx mechanism of action involves retinal irradiance distribution modifications that may stimulate patient use of functional, rather than atrophied, retinal regions.
Funder
Optimal Acuity Corporation
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献